GB2037565A - Electrolyte drink - Google Patents
Electrolyte drink Download PDFInfo
- Publication number
- GB2037565A GB2037565A GB7941451A GB7941451A GB2037565A GB 2037565 A GB2037565 A GB 2037565A GB 7941451 A GB7941451 A GB 7941451A GB 7941451 A GB7941451 A GB 7941451A GB 2037565 A GB2037565 A GB 2037565A
- Authority
- GB
- United Kingdom
- Prior art keywords
- ions
- mixture
- sodium
- phosphate
- meq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003792 electrolyte Substances 0.000 title abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 17
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 17
- 229960001031 glucose Drugs 0.000 claims abstract description 17
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 13
- 239000008121 dextrose Substances 0.000 claims abstract description 13
- 239000005720 sucrose Substances 0.000 claims abstract description 13
- 229960004793 sucrose Drugs 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 11
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 7
- 235000008160 pyridoxine Nutrition 0.000 claims abstract description 7
- 239000011677 pyridoxine Substances 0.000 claims abstract description 7
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 7
- 229940001468 citrate Drugs 0.000 claims abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- -1 sulphate ions Chemical class 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 6
- 235000005979 Citrus limon Nutrition 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 229910001414 potassium ion Inorganic materials 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 235000019800 disodium phosphate Nutrition 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 244000248349 Citrus limon Species 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000008122 artificial sweetener Substances 0.000 claims description 2
- 235000021311 artificial sweeteners Nutrition 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- 235000015165 citric acid Nutrition 0.000 claims 1
- BUKHSQBUKZIMLB-UHFFFAOYSA-L potassium;sodium;dichloride Chemical compound [Na+].[Cl-].[Cl-].[K+] BUKHSQBUKZIMLB-UHFFFAOYSA-L 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 229960001790 sodium citrate Drugs 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 3
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 229920002527 Glycogen Polymers 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 8
- 230000035882 stress Effects 0.000 description 8
- 229960003975 potassium Drugs 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 235000011008 sodium phosphates Nutrition 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- 206010027423 Metabolic alkalosis Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 208000019025 Hypokalemia Diseases 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940085991 phosphate ion Drugs 0.000 description 3
- 208000007645 potassium deficiency Diseases 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940077731 carbohydrate nutrients Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000758 acidotic effect Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000020006 fruit beer Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006609 metabolic stress Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000019980 sodium acid phosphate Nutrition 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A chemical composition for reconstituting with water to provide an electrolyte drink intended for consumption by animals, especially human beings. The drink permits replacement of essential body constituents lost as a result of metabolic processes. The composition comprises Na<+>, K<+>, Mg<2+>, Cl<->, SO42-, PO42-, citrate, sucrose, dextrose, ascorbic acid and pyridoxine.
Description
SPECIFICATION
Electrolyte drink
This invention relates to an electrolyte drink useful for replenishing the major constituents lost from body fluids as a result of metabolic processes. While the drink is mainly intended for use by humans and is described in that context, it is to be understood that it can equally be used by animals such as horses and dogs.
There are presently a substantial number of electrolyte drinks on the market which are alleged to replenish essential electrolytes and water lost from the body during physical activity. Such products are, however, generally unpalatable and do not, in fact, satisfy the body completely by replenishing all the essential constituents which are lost.
It is therefore an object of the invention to provide a drink which overcomes these defects and, furthermore, permits quick recovery of the body following strenuous activity.
The invention is based upon a number of new discoveries and known scientific data which can be summarized as follows:
(1) The unpleasant taste of electrolytes in drinks can be masked by carefully balancing the relative ratios of the electrolytes.
(2) Electrolytes in correct physiological quantities increase the efficiency of the body to utilize glycogen and improve muscular activities.
(3) Against the traditional concept that massive protein intake will efficiently increase muscular glycogen storage, experimentation in racing animals indicates that carbohydrates such as a simple combination of sucrose, glucose and citrate in the presence of electrolytes is a more efficient glycogen source. Carbohydrate as a glycogen source induces less stress in the metabolic system.
(4) The role of potassium is extremely important in oral electrolyte therapy to combat stress and in sugar absorption in the gastro intestinal tract. Clinical observations of racing animals and athletes performances indicates potassium deficiency is far more common. Supplementation in correct quantities and qualities reduces physical and metabolic stress and improves performance.
(5) Potassium otherthan in the form of potassium chloride induces potassium deficiency and alkalosis.
Use of potassium citrate, gluconate, carbonate or phosphate as the potassium source is not suitable.
(6) Oral magnesium has to be provided at a level of three times the required theoretical level as only one third is absorbed through the intestine.
(7) Supplementation of pyridoxine in high doses and in combination with ascorbic acid greatly reduces the stress effect on the metabolic system of the body by increasing the metabolic "Purification" process in the liver and kidney.
(8) Buffer agents can improve glycogen utilization.
(9) Physical stress induces metabolic alkalosis and
not metabolic acidosis as commonly believed. The
presence of acid in the urine does not conclude the
body is acidotic.
(10) Hydrated ions such as phosphate ions cannot be replaced by their chemically equivalent anhydrous salt. e.g. Sodium phosphate B.P. (Na2HP04.
12H20) cannot be substituted by Na2HPO4 anhydrous.
Experimentation indicates that although both are chemically identical when dissolved in water, they do not perform the same physiologically. The water of crystallisation in the case of sodium phosphate
B.P. is chemically attached to the phosphate ion. It is in such a form that the intracellular substrate can utilize the phosphate as a buffer. Dissolving sodium phosphate an hydros in water does not necessitate the attachment of water molecules to the phosphate ion. In fact this process of hydration is performed intracellularly, and requires energy. Ingestion of anhydrous sodium phosphate leads to additional stress on the intracellular substrate and dehydrates the cells. However if sodium phosphate B.P. is used as a source of phosphate and buffer, the intracellular substrate can utilize the available phosphate ion readily.
According to the present invention there is provided a mixture suitable for reconstituting with water to form a highly palatable drink which comprises sodium ions, potassium ions which have been derived from potassium chloride, magnesium ions, chloride ions, sulphate ions, phosphate ions as herein defined, citrate ions, sucrose, dextrose, ascorbic acid and pyridoxine, wherein the relative ratio ofthe ions sodium: potassium: magnesium: chloride: sulphate: phosphate is 5-7:3-5:1-3:5-6:1-3:5-7 calculated on a milliequivalent basis.
The phosphate ions referred to above and in the claims are defined as those ions which are produced upon the dissolution of hydrated disodium hydrogen phosphate and hydrated sodium dihydrogen phosphate in aqueous solution.
If desired a flavouring agent such as TRUSIL
LEMON ELITE (the trade name of a commercial lemon flavouring agent supplied by Bush, Boake & BR<
Allan), may be incorporated in the mixture to provide a particularly pleasant flavour on the palate.
Artificial sweeteners, colourings and preservatives may likewise be incorporated.
The phosphate and the citrate present in the mixture also function as a buffer system to maintain the drink within a desirable pH range. This pH range is preferably 6.8 to 7.4.
Preferably, the sucrose, dextrose and citrate is present in sufficient quantity to provide 3.4 Kcal of energy for every gram of mixture. This energy may be supplied by a mixture of 0.48 gram of sucrose, 0.318 gram of dextrose, 42 mg. of citric acid and 12 mg of sodium citrate.
The quantity of ascorbic acid is preferably 10 mg for every gram of concentrate and the pyridoxine is
ideally present in an amount of 2.5 mg per gram of concentrate.
The drink which is produced from the mixture
according to the present invention has the following
properties:
(a) There is no saline taste as in conventional electrolyte drinks.
(b) It is a complete electrolyte replacement in the
sense that it caters for the complete needs of the
body physiologically. The electrolytes presented are
balanced to the natural body daily requirement. This
enables the body to absorb and use the electrolyte
raw material to repair or replenish any deficiency and aid the body to quick recovery from stress.
(c) It contains a series of simple carbohydrates, viz.
sucrose, dextrose and citrate, as a readily usable energy source. The body can make use of this immediately or build up the glycogen depot in the liver or muscles. The high glycogen level in the liver protects the liver and reduces cholesterol production.
(d) It provides a detoxifying effect mainly due to the presence of pyridoxine and ascorbic acid which aids the liverto efficiently metabolise and dispose unwanted harmful materials (alcohol, nitrogen waste etc.).
(e) The feeling of thirst, is stimulated both by a lower extracellular volume and a high plasma osmolarity. The present drink contains balanced electrolytes to provide for immediate adjustments, and hence satisfies the sensation of thirst
(f) It provides potassium and sodium in its natural form of chlorides, and magnesium as sulphates as in the correct daily body requirement ratio. In addition, the phosphate rapidly helps to restore the body fluid to neutrality.
(g) It provides the blood with glucose. Unused glucose is automatically converted to glycogen and stored in the liver or muscle. It has generally been misunderstood that to increase glycogen storage to the maximum, vast quantities of protein should be ingested. However two convert protein to glycogen involves far more complicated and energy demanding metabolic processes. This is highly inefficient and wasteful of energy. In addition excess nitrogen waste from protein digestion also increases the demand, on the liver and kidney waste disposal system as excess nitrogen waste has to be dealt with to maintain the body free of metabolic alkalosis. In cases of potassium deficiency, the presence of ammonia enhances the metabolic alkalosis stress on the body buffering systems. In severe cases, this can be the major cause of kidney impairment.This fact has been repeatedly proven to be correct in racing greyhounds which have a diet consisting of a vast excess of meat and are subjected to severe racing stress.
(h) It improves the energy efficiency in the body. In
Sydney University, athletes were required to perform a set work load in a given time under controlled laboratory conditions. Measurement of the heat generation by the body was used as a tool to meas
ure the efficiency of the muscles to perform the work. The result was thatthe body temperature rise was significantly less when the present drink is
ingested half an hour before the workout, as com
pared to a salt and dextrose mixture, water, fruit juice, beer and a known brand of electrolyte supple
ment. Body weight loss was also dramatically
reduced.
(i) Potassium being a major intracellular compo
nent is provided in drink formulation. A depletion of
potassium leads to a decrease in action potential of
muscle and also causes metabolic alkalosis. The
present drink overcomes this problem.
(j) It supplies the two natural body buffers, viz. the
phosphate buffer and the citrate buffer.
(k) It counteracts the effect of alcohol by providing vitamins B6 and C to aid alcohol metabolism in liver,
increasing glycogen storage in the liver which acts as a protectant, replacing electrolytes lost, restoring the glucose level in the blood which supplies the brain, providing buffers to aid alcohol by-product disposal and neutralising excess gastric hydrochloric acid secretion caused by alcohol irritation on the stomach wall.
(I) Diarrhoea and vomiting causes severe dehydration through loss of water and electrolytes. The present drink replenishes such losses and restores body fluid volume and osmolarity.
(m) It is a balanced mineral source.
A preferred embodiment of the invention will now be described in the following example.
EXAMPLE
A first mixture was prepared by blending 480 mg of disodium hydrogen phosphate (Na2HPO4 12H20) with 4.8 g of sucrose and 3.18 g of dextrose.
A second mixture was prepared by blending the following ingredients in the stated amounts.
Sodium Chloride 69.6 mg.
Potassium Chloride 288.0 mg.
Magnesium Sulphate (anhydrous) 148.0 mg.
Sodium Citrate 120.0 mg.
Sodium Acid Phosphate 111.6 mg.
Ascorbic Acid 100.0 mg.
Pyridoxine Hydrochloride 25.0 mg.
Citric Acid 420.0 mg.
Lemon Flavouring 257.8 mg.
The two mixtures were then blended together and milled to 100 mesh size to form a drink concentrate containing, for each 10 gm. 6.1 mEq sodium ions, 3.85 mEq potassium ions, 2.47 mEq magnesium ions, 5.0 mEq chloride ions, 2.47 mEq sulphate ions, 6.25 mEq phosphate ions, and 7.22 mEq citrate ions.
The product was a drink concentrate suitable for reconstituting with water to form a palatable drink.
Claims (11)
1. A mixture suitable for reconstituting with water to form a drink which comprises sodium ions, potassium ions which have been derived from potassium chloride, magnesium ions, chloride ions, sulphate ions, phosphate ions as herein defined, citrate ions, sucrose, dextrose, ascorbic acid and pyridoxine, wherein the relative ratio of the ions sodium: potassium: magnesium : chloride: sul phate: phosphate is 5-7 :3-5 : 3-5:1-3 : 5-6:1-3 : 5-7 calculated on a milliequivalent basis.
2. A mixture as claimed in claim 1 and including a flavouring agent.
3. A mixture as claimed in claim 1 or 2 and
including an artificial sweetener and/or colouring and/or preservative.
4. A mixture as claimed in any of claims 1 to 3 which when reconstituted with water has a pH which is buffered within the range of 6.8 to 7.4.
5. A mixture as claimed in any one of claims 1-4 which contains a sufficient quantity of sucrose, dextrose and citrate to provide 3.4 Kcal of energy for
every gram of mixture.
6. A mixture as claimed in claim 5 wherein for every gram of mixture there is 0.48 gram of sucrose, 0.31 gram of dextrose and 7.22 milliequivalents of citrate.
7. A mixture as claimed in any one of claims 1-6 wherein for every gram of mixture there is 10 mg of ascorbic acid and 2.5 mg of pyridoxine.
8. A mixture suitable for reconstituting with water to form a drink which comprises 6.1 mEq sodium ions, 3.85 mEq potassium ions, 2.47 mEq magnesium ions, 5.0 mEq chloride ions, 2.47 mEq sulphate ions, 6.25 mEq phosphate ions as herein defined, 7.22 mEq citrate ions, 100 mg ascorbic acid, 25 mg pyridoxine, 4.8 g sucrose, 3.1 g dextrose, and lemon flavouring q.s., per 10 grams of mixture.
9. A drink concentrate which comprises an admixture of sodium chloride potassium chloride anhydrous magnesium sulphate, hydrated disodium hydrogen, phosphate, hydrated sodium hydrogen phosphate, dextrose, sucrose, ascorbic acid, pyridoxine hydrochloride, sodium citrate and citric acid.
10. A drink concentrate as claimed in claim 9 wherein the ingredients are present in the following amounts (for each 10 gm.):
Sodium Chloride 69.6 mg
Potassium Chloride 288.0 mg.
Magnesium Sulphate 148.0 mg.
Sodium Citrate 120.0 mg.
Disodium hydrogen Phosphate 480.0 mg.
Sodium dihydrogen Phosphate 111.6 mg.
Ascorbic Acid 100.0 mg.
Pyridoxine Hydrochloride 25.0 mg.
Citric Acid 420.0 mg.
Sucrose 4.8 gm.
Dextrose 3.18 gm
Lemon Flavouring 257.8 mg.
11. A mixture as claimed in claim 1 substantially as described in the Example.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU707778 | 1978-12-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2037565A true GB2037565A (en) | 1980-07-16 |
| GB2037565B GB2037565B (en) | 1983-03-23 |
Family
ID=3697684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB7941451A Expired GB2037565B (en) | 1978-12-11 | 1979-11-30 | Electrolyte drink |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS5581575A (en) |
| AU (1) | AU526503B2 (en) |
| GB (1) | GB2037565B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0085295A3 (en) * | 1982-01-12 | 1984-03-21 | Natrex Diatetika, E. Baltensperger | Drinks and liquid foods with a low sodium level |
| EP0117653A1 (en) * | 1983-02-01 | 1984-09-05 | The Procter & Gamble Company | Beverages containing specific cation-edible acid mixtures for improved flavor impression |
| EP0141250A3 (en) * | 1983-10-10 | 1986-07-16 | Natrex Diatetika, E. Baltensperger | Beverage with a high magnesium content |
| US4853237A (en) * | 1986-10-16 | 1989-08-01 | Oy Sinebrychoff Ab | Fitness drink powder |
| EP0353065A1 (en) * | 1988-07-29 | 1990-01-31 | University Of Florida | Compositions and methods for achieving improved physiological response to exercise |
| US4994283A (en) * | 1987-07-02 | 1991-02-19 | The Procter & Gamble Company | Iron-calcium mineral supplements with enhanced bioavailability |
| US5032411A (en) * | 1990-02-27 | 1991-07-16 | University Of Texas System Board Of Regents | Beverage compositions for human consumption |
| EP1176948A4 (en) * | 1999-05-03 | 2007-06-20 | Drugtech Corp | Anti-nausea compositions and methods |
| WO2022066868A1 (en) * | 2020-09-25 | 2022-03-31 | Abbott Laboratories | Ready-to-drink carbonated electrolyte beverage |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE181988T1 (en) * | 1984-11-23 | 1986-11-27 | Aktiebolaget Pripps Bryggerier, Bromma | PRODUCT FOR BEVERAGES. |
| JPH0256579U (en) * | 1988-10-19 | 1990-04-24 | ||
| US8034372B2 (en) * | 2003-03-05 | 2011-10-11 | Nestec, Ltd. | Dietary supplement for athletic pets |
| JP7211881B2 (en) * | 2019-04-12 | 2023-01-24 | サントリーホールディングス株式会社 | Beverages containing sodium, potassium, and citric acid |
| WO2020209300A1 (en) * | 2019-04-12 | 2020-10-15 | サントリーホールディングス株式会社 | Beverage containing sodium and organic acid |
| JP7211880B2 (en) * | 2019-04-12 | 2023-01-24 | サントリーホールディングス株式会社 | Beverage containing sodium, potassium and ascorbic acid |
| JP7211879B2 (en) * | 2019-04-12 | 2023-01-24 | サントリーホールディングス株式会社 | Beverage containing sodium and gluconic acid |
-
1978
- 1978-12-11 AU AU52035/79A patent/AU526503B2/en not_active Ceased
-
1979
- 1979-11-27 JP JP15414779A patent/JPS5581575A/en active Granted
- 1979-11-30 GB GB7941451A patent/GB2037565B/en not_active Expired
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0085295A3 (en) * | 1982-01-12 | 1984-03-21 | Natrex Diatetika, E. Baltensperger | Drinks and liquid foods with a low sodium level |
| EP0117653A1 (en) * | 1983-02-01 | 1984-09-05 | The Procter & Gamble Company | Beverages containing specific cation-edible acid mixtures for improved flavor impression |
| EP0141250A3 (en) * | 1983-10-10 | 1986-07-16 | Natrex Diatetika, E. Baltensperger | Beverage with a high magnesium content |
| US4853237A (en) * | 1986-10-16 | 1989-08-01 | Oy Sinebrychoff Ab | Fitness drink powder |
| US4994283A (en) * | 1987-07-02 | 1991-02-19 | The Procter & Gamble Company | Iron-calcium mineral supplements with enhanced bioavailability |
| EP0353065A1 (en) * | 1988-07-29 | 1990-01-31 | University Of Florida | Compositions and methods for achieving improved physiological response to exercise |
| US5032411A (en) * | 1990-02-27 | 1991-07-16 | University Of Texas System Board Of Regents | Beverage compositions for human consumption |
| EP1176948A4 (en) * | 1999-05-03 | 2007-06-20 | Drugtech Corp | Anti-nausea compositions and methods |
| WO2022066868A1 (en) * | 2020-09-25 | 2022-03-31 | Abbott Laboratories | Ready-to-drink carbonated electrolyte beverage |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2037565B (en) | 1983-03-23 |
| JPS5581575A (en) | 1980-06-19 |
| AU526503B2 (en) | 1983-01-13 |
| JPS6332766B2 (en) | 1988-07-01 |
| AU5203579A (en) | 1980-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4322407A (en) | Electrolyte drink | |
| EP0040654B1 (en) | Electrolyte drink concentrate | |
| GB2037565A (en) | Electrolyte drink | |
| US6039987A (en) | Physical endurance drink and method of preventing cramping caused by strenuous bodily activity | |
| US5114723A (en) | Beverage compositions for human consumption | |
| JP3708115B2 (en) | Mixed calcium and vitamin D supplements | |
| US5032411A (en) | Beverage compositions for human consumption | |
| DE60008238T2 (en) | COMPOSITIONS CONTAINING CREATINE IN THE FORM OF A SUSPENSION | |
| JPH07236460A (en) | Creatine beverage and manufacturing method thereof | |
| JP2004504824A (en) | Fiber formula | |
| CN101049150B (en) | Edible nourishment health care potassium salt with extensive use | |
| JPH08224073A (en) | Creatine veberage and its production | |
| JP3085889B2 (en) | How to make jelly for energy supplementation | |
| CN102715606A (en) | Beverage | |
| US20060172016A1 (en) | Muscle cramp reliever | |
| US20200054045A1 (en) | All-Natural Drink Composition for Synthesizing and Regenerating Adenosine Triphosphate (ATP) in Muscle Cells and Neurons, Repairing Exercise-Induced Muscle Fiber Damage, Repletion of Glycogen Stores in the Muscle and Liver, Enhancing Blood Flow to Tissue during Intense Exercise, and Preventing and Reducing Oxidative Damage to Tissues during Exercise with Minimal Gastrointestinal Disturbances | |
| WO2001093692A2 (en) | New canine beverage | |
| RU2296491C1 (en) | Beverage with pulp | |
| JP2007314560A (en) | Agents that sustain oxidative metabolism that accompanies exercise | |
| JPS59203481A (en) | Health carbonated drinking water | |
| JPH05276904A (en) | Beverage composition for young child | |
| JP2564648B2 (en) | Liquid food additive containing high concentration of ionized calcium, method for producing the same, and processed food to which the food additive is added | |
| WO1998046091A1 (en) | Sports drink and drink powder | |
| CN1097097A (en) | Active calcium chewing gum | |
| KR19980014732A (en) | Manufacturing method of dietary cotton based on seaweed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19951130 |